<?xml version="1.0" encoding="UTF-8"?>
<ref id="R41">
 <label>41</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>El-Khoueiry</surname>
    <given-names>AB</given-names>
   </name>, 
   <name name-style="western">
    <surname>Sangro</surname>
    <given-names>B</given-names>
   </name>, 
   <name name-style="western">
    <surname>Yau</surname>
    <given-names>T</given-names>
   </name>, 
   <etal>et al</etal>
  </person-group>
  <article-title>Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial</article-title>. 
  <source>Lancet</source>
  <year>2017</year>;
  <volume>389</volume>:
  <fpage>2492</fpage>â€“
  <lpage>502</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S0140-6736(17)31046-2</pub-id>
  <?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/28434648?>
  <pub-id pub-id-type="pmid">28434648</pub-id>
 </mixed-citation>
</ref>
